Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
In 2026, Optavia launched HSA/FSA eligibility and a GLP-1 medication support track through its LifeMD partnership signs of a company adapting, not collapsing
Retatrutide goes one step further: Its the first triple agonist, meaning it works on GLP-1, GIP, and glucagon
Though Retatrutide is not yet FDA-approved, its potential effectiveness shows great promise, as evidenced by the TRIUMPH-1 Phase 3 trials that demonstrated up to 28.3% weight loss over 80 weeks
Some patients report improved sleep quality, which is consistent with the known neurological effects of glycine at higher supplemental doses
US$ 21.90
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 23.23
US$ 27.63
US$ 29.97
US$ 25.60
